A CASE OF HYPERCHOLESTEROLEMIA HYPORESPONDER TO iPCSK9 – CASE REPORT
Anno:
2025
Introduction: The expected response to iPCSK9 therapy in terms of LDL-C reduction is around 60% in monotherapy. In this clinical case we present an example of hyporesponse to therapy with monoclonal antibody (alirocumab) used in monotherapy. Presentation of the case: Patient F, 77 years old, hospitalized in march 2018 for lateral…